Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Other

August 17, 2021

Does Lifescan’s Expanded Partnership with Cecelia Health Signal a New Business Model to Set Up for an Acquisition by Livongo?

Here is a brief preview of this blast: Lifescan and Cecelia Health announced the expansion of a multi-year partnership to offer users a fully integrated live telehealth service with the OneTouch Reveal app. Recall, Lifescan and Cecelia Health initially entered into the partnership in October 2020 starting with text-based coaching. According to the press release, Lifescan and Cecelia Health will launch a new, live Certified Diabetes Care and Education Specialists (CDCES) telehealth service through the OneTouch Reveal app which will be fully integrated into OneTouch Solutions. Below, FENIX provides thoughts on Lifescan’s apparent new strategy to expand its business model beyond traditional PBM reimbursement to either remain competitive or become attractive as an acquisition target.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.